FDA Questions Safety Of Genzyme's Kynamro
Genzyme Corp.'s bid for approval of cholesterol disorder treatment Kynamro is facing a potential setback, after a U.S. Food and Drug Administration research report released Tuesday flagged a number of concerns...To view the full article, register now.
Already a subscriber? Click here to view full article